Form 4: Precision BioSciences Director, Shari Lisa Pire, Acquires 9,826 Restricted Stock Units

Director Shari Lisa Pire acquired 9,826 Restricted Stock Units in Precision BioSciences, vesting on June 4, 2025, or the day before the next annual meeting.

Summary

• Shari Lisa Pire, a director of Precision BioSciences Inc. (DTIL), reported the acquisition of 9,826 Restricted Stock Units (RSUs) on June 4, 2024.
• Each RSU represents a contingent right to receive one share of Precision BioSciences' Common Stock or an equivalent amount of cash.
• The RSUs vest on the earlier of June 4, 2025, or the day before the company's next annual meeting of stockholders, contingent upon continued service to the issuer.

Sentiment

Score: 7

Explanation: The acquisition of RSUs by a director is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction and doesn't provide significant new information.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service to the company, aligning her interests with the long-term success of Precision BioSciences.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates